{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T06:42:23Z","timestamp":1779345743269,"version":"3.51.4"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec>\n<jats:title>Background and Objective<\/jats:title>\n<jats:p>Type 1 diabetes mellitus (T1DM) is characterized by the loss of pancreatic cells, resulting in total insulin insufficiency. According to the Diabetes Control and Complications Trial, T1DM treatment aims to achieve appropriate glycemic control and to prevent and avoid repeated episodes of hypoglycemia. Insulin therapy alone addresses the symptoms of the disease but fails to target the underlying pathophysiology of T1DM in children despite continuous efforts to enhance insulin regimens. Therefore, immunotherapy-based approaches have been considered potential treatments for T1DM in children since they can regulate the autoimmune responses and enhance the children\u2019s quality of life by reducing their daily dose intake of insulin.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>In this meta-analysis, we have covered a few immunotherapeutic options based on preclinical and clinical data, namely, Teplizumab, Golimumab, Imatinib, Etanercept, Canakinumab, Ladarixin, Ala-Ala, Anakinra, and Otelixizumab in reliable databases such as Pubmed, Google Scholar, and Cochrane. SPSS was used for statistical analysis. Mean difference (MD) and standard mean difference (SMD) were used to evaluate the outcomes with a 95% confidence interval (CI).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>To assess the effect of immunotherapy on the patients\u2019 daily dosage of insulin and their HbA1c and C-peptide levels, data from twelve trials were combined and synthesized. Because of the high levels of heterogeneity in the selected studies, a random-effects model was used for analysis.<\/jats:p>\n<jats:p>The combined data showed that patients receiving immunotherapy had higher C-peptide levels (Mean Difference (MD) = 1.51; 95% Confidence Interval (CI): [-2.56, 5.58]); however, this difference was not statistically significant (p = 0.42). On the other hand, patients in the immunotherapy group had significantly decreased HbA1c levels (MD = -0.63; 95% CI: [-1.18, -0.07]; p = 0.03), indicating that immunotherapy had a positive impact on glycemic management. Additionally, patients receiving immunotherapy exhibited a drop in their daily insulin dosage (MD = -1.15; 95% CI: [-2.59, 0.28]); however, this drop failed to achieve statistical significance (p = 0.10), thus indicating the need for additional research.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>This meta-analysis aimed to assess the effectiveness of immunotherapy in treating T1DM by examining its effects on the patients\u2019 required dose of insulin, C-peptide, and HbA1c levels. While some studies failed to show desired results, the overall effect was an increase in C-peptide levels and a decrease in HbA1c levels. However, the study did not achieve statistical significance for insulin dosing. The main study\u2019s strength is its focus on randomized clinical trials which is considered among the highest levels of epidemiological evidence. Therefore, further research is required to minimize the gaps and to explore immunotherapy-based drugs as potential treatments for T1DM.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0321727","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T17:25:14Z","timestamp":1744392314000},"page":"e0321727","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Immunotherapy as a treatment for type 1 diabetes mellitus in children and young adults: A comprehensive systematic review and meta-analysis"],"prefix":"10.1371","volume":"20","author":[{"given":"Gaelle","family":"Salame","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Hakim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Dagher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rose-Mary","family":"Daou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6839-7618","authenticated-orcid":true,"given":"Anthony El","family":"Dada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lea","family":"Nassif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilda E.","family":"Ghadieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sami","family":"Azar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samer","family":"Bazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5882-1619","authenticated-orcid":true,"given":"Frederic","family":"Harb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"issue":"5","key":"pone.0321727.ref001","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S2213-8587(20)30042-5","article-title":"Risk factors and prevention strategies for diabetic ketoacidosis in people with established type 1 diabetes","volume":"8","author":"D Ehrmann","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"pone.0321727.ref002","author":"CDC. About Type 1 Diabetes","year":"2025"},{"key":"pone.0321727.ref003","doi-asserted-by":"crossref","first-page":"154842","DOI":"10.1016\/j.metabol.2021.154842","article-title":"Diabetic ketoacidosis in pediatric patients with type 1- and type 2 diabetes during the COVID-19 pandemic","volume":"122","author":"C Loh","year":"2021","journal-title":"Metabolism"},{"issue":"2","key":"pone.0321727.ref004","doi-asserted-by":"crossref","first-page":"98","DOI":"10.34172\/hpp.2020.18","article-title":"Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis","volume":"10","author":"M Mobasseri","year":"2020","journal-title":"Health Promot Perspect"},{"key":"pone.0321727.ref005","article-title":"Diabetes","author":"Organization WH","year":"2024"},{"issue":"8","key":"pone.0321727.ref006","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s40618-017-0641-y","article-title":"Immunotherapy for type 1 diabetes","volume":"40","author":"D Frumento","year":"2017","journal-title":"J Endocrinol Invest"},{"issue":"8499","key":"pone.0321727.ref007","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0140-6736(86)91943-4","article-title":"Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a\u00a0multicenter\u00a0double-blind trial","volume":"2","author":"G Feutren","year":"1986","journal-title":"Lancet"},{"issue":"1","key":"pone.0321727.ref008","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cmet.2019.11.017","article-title":"New Frontiers in the Treatment of Type 1 Diabetes","volume":"31","author":"JT Warshauer","year":"2020","journal-title":"Cell Metab"},{"issue":"1","key":"pone.0321727.ref009","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00125-023-06014-2","article-title":"A first-in-human, open-label Phase 1b and a\u00a0randomized, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab","volume":"67","author":"C Mathieu","year":"2024","journal-title":"Diabetologia"},{"issue":"2","key":"pone.0321727.ref010","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00125-020-05317-y","article-title":"A\u00a0randomized, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes","volume":"64","author":"B Keymeulen","year":"2021","journal-title":"Diabetologia"},{"key":"pone.0321727.ref011","doi-asserted-by":"crossref","first-page":"694118","DOI":"10.3389\/fimmu.2021.694118","article-title":"Hematopoietic Stem Cells in Type 1 Diabetes","volume":"12","author":"I Pastore","year":"2021","journal-title":"Front Immunol"},{"issue":"5","key":"pone.0321727.ref012","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s12015-021-10250-7","article-title":"Circulating Hematopoietic (HSC) and Very-Small Embryonic like (VSEL) Stem Cells in Newly Diagnosed Childhood Diabetes type 1 - Novel Parameters of Beta Cell Destruction\/Regeneration Balance and Possible Prognostic Factors of Future Disease Course","volume":"18","author":"M Jamio\u0142kowska-Sztabkowska","year":"2022","journal-title":"Stem Cell Rev Rep"},{"issue":"1","key":"pone.0321727.ref013","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13287-024-03636-0","article-title":"Current status of stem cell therapy for type 1 diabetes: a critique and a prospective consideration","volume":"15","author":"MA Ghoneim","year":"2024","journal-title":"Stem Cell Res Ther"},{"issue":"20","key":"pone.0321727.ref014","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.3390\/nu14204391","article-title":"Comparison of the Effectiveness of Low Carbohydrate Versus Low Fat Diets, in Type 2 Diabetes: Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"14","author":"TA Apekey","year":"2022","journal-title":"Nutrients"},{"issue":"9790","key":"pone.0321727.ref015","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(11)60931-8","article-title":"Teplizumab for treatment of type 1 diabetes (Prot\u00e9g\u00e9 study): 1-year results from a\u00a0randomized, placebo-controlled trial","volume":"378","author":"N Sherry","year":"2011","journal-title":"Lancet"},{"issue":"8","key":"pone.0321727.ref016","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S2213-8587(21)00139-X","article-title":"Imatinib therapy for patients with recent-onset type 1 diabetes: a\u00a0multicenter,\u00a0randomized, double-blind, placebo-controlled, phase 2 trial","volume":"9","author":"SE Gitelman","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"pone.0321727.ref017","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.2337\/db13-0345","article-title":"Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders","volume":"62","author":"KC Herold","year":"2013","journal-title":"Diabetes"},{"issue":"7","key":"pone.0321727.ref018","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.2337\/dc09-0054","article-title":"Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study","volume":"32","author":"L Mastrandrea","year":"2009","journal-title":"Diabetes Care"},{"issue":"9881","key":"pone.0321727.ref019","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/S0140-6736(13)60023-9","article-title":"Interleukin-1 antagonism in type 1 diabetes of recent onset: two\u00a0multicenter,\u00a0randomized, double-blind, placebo-controlled trials","volume":"381","author":"A Moran","year":"2013","journal-title":"Lancet"},{"issue":"9","key":"pone.0321727.ref020","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1111\/dom.14770","article-title":"Ladarixin, an inhibitor of the interleukin-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: A\u00a0multicenter, randomized, double-blind, placebo-controlled trial","volume":"24","author":"L Piemonti","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"21","key":"pone.0321727.ref021","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1056\/NEJMoa2006136","article-title":"Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes","volume":"383","author":"T Quattrin","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"pone.0321727.ref022","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.2337\/dc13-0327","article-title":"Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes","volume":"37","author":"R Aronson","year":"2014","journal-title":"Diabetes Care"},{"issue":"6","key":"pone.0321727.ref023","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.2337\/diabetes.54.6.1763","article-title":"A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes","volume":"54","author":"KC Herold","year":"2005","journal-title":"Diabetes"},{"issue":"23","key":"pone.0321727.ref024","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa2308743","article-title":"Teplizumab and \u03b2-Cell Function in Newly Diagnosed Type 1 Diabetes","volume":"389","author":"EL Ramos","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"pone.0321727.ref025","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1210\/clinem\/dgae048","article-title":"Comparisons of Metabolic Measures to Predict T1D vs Detect a Preventive Treatment Effect in High-Risk Individuals","volume":"109","author":"EK Sims","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"pone.0321727.ref026","doi-asserted-by":"crossref","first-page":"154804","DOI":"10.1016\/j.metabol.2021.154804","article-title":"The IL-8-CXCR1\/2 axis contributes to diabetic kidney disease","volume":"121","author":"C Loretelli","year":"2021","journal-title":"Metabolism"},{"key":"pone.0321727.ref027","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.phrs.2014.07.004","article-title":"The rise, fall, and resurgence of immunotherapy in type 1 diabetes","volume":"98","author":"M Ben Nasr","year":"2015","journal-title":"Pharmacol Res"},{"key":"pone.0321727.ref028","doi-asserted-by":"crossref","first-page":"107157","DOI":"10.1016\/j.phrs.2024.107157","article-title":"The opportunities and challenges of the disease-modifying immunotherapy for type 1 diabetes: A systematic review and meta-analysis","volume":"203","author":"C Lin","year":"2024","journal-title":"Pharmacol Res"},{"issue":"6","key":"pone.0321727.ref029","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.4049\/jimmunol.2001127","article-title":"Regulatory B Cells in Autoimmune Diabetes","volume":"206","author":"M Ben Nasr","year":"2021","journal-title":"J Immunol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0321727","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T17:25:22Z","timestamp":1744392322000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0321727"}},"subtitle":[],"editor":[{"given":"Paolo","family":"Fiorina","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":29,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0321727","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]}}}